These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27061810)

  • 21. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
    Starling N; Vázquez-Mazón F; Cunningham D; Chau I; Tabernero J; Ramos FJ; Iveson TJ; Saunders MP; Aranda E; Countouriotis AM; Ruiz-Garcia A; Wei G; Tursi JM; Guillen-Ponce C; Carrato A
    Ann Oncol; 2012 Jan; 23(1):119-127. PubMed ID: 21447616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
    Koizumi W; Boku N; Yamaguchi K; Miyata Y; Sawaki A; Kato T; Toh Y; Hyodo I; Nishina T; Furuhata T; Miyashita K; Okada Y
    Ann Oncol; 2010 Apr; 21(4):766-771. PubMed ID: 19828562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line Palliative Chemotherapy for Colorectal Cancer: a Population-based Analysis of Delivery and Outcomes in a Single-payer Health System.
    Wilson BE; Booth CM; Patel S; Berry S; Kong W; Merchant SJ
    Clin Oncol (R Coll Radiol); 2024 Apr; 36(4):211-220. PubMed ID: 38199907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.
    Kagawa Y; Wang C; Piao Y; Jin L; Tanizawa Y; Cai Z; Sunakawa Y
    Target Oncol; 2024 Jul; 19(4):575-585. PubMed ID: 38691296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
    Kodama T; Imajima T; Shimokawa M; Otsuka T; Kawahira M; Nakazawa J; Hori T; Shibuki T; Arima S; Ido A; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Sakai K; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 May; 14(1):12422. PubMed ID: 38816500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
    Ahn DH; Barzi A; Ridinger M; Samuëlsz E; Subramanian RA; Croucher PJP; Smeal T; Kabbinavar FF; Lenz HJ
    Clin Cancer Res; 2024 May; 30(10):2039-2047. PubMed ID: 38231047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
    Crea F; Fornaro L; Paolicchi E; Masi G; Frumento P; Loupakis F; Salvatore L; Cremolini C; Schirripa M; Graziano F; Ronzoni M; Ricci V; Farrar WL; Falcone A; Danesi R
    Ann Oncol; 2012 May; 23(5):1207-1213. PubMed ID: 21926398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
    Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
    Luo W; Liao WJ; Ma L; Huang YT; Shi M; Wen Q; Wang XN
    Cancer Immunol Immunother; 2010 Feb; 59(2):247-56. PubMed ID: 19652968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
    Barone C; Nuzzo G; Cassano A; Basso M; Schinzari G; Giuliante F; D'Argento E; Trigila N; Astone A; Pozzo C
    Br J Cancer; 2007 Oct; 97(8):1035-9. PubMed ID: 17895897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study.
    Bir Yücel K; Uğraklı M; Sekmek S; Yıldırım N; Gürler F; Yazıcı O; Özet A; Bal Ö; Araz M; Artaç M; Özdemir N
    Curr Med Res Opin; 2024 Jul; 40(7):1137-1143. PubMed ID: 38857167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
    Erol C; Sendur MAN; Bilgetekin I; Garbioglu DB; Hamdard J; Akbas S; Hizal M; Arslan C; Sevinc A; Kucukarda A; Erdem D; Kahraman S; Cakir E; Demirkiran A; On S; Dogan I; Erdogan AP; Koca S; Kubilay P; Eren OO; Cilbir E; Celik E; Araz M; Ozyukseler DT; Yildirim ME; Bahceci A; Taskaynatan H; Oyman A; Deniz GI; Menekse S; Kut E; Gulmez A; Sakin A; Nayir E; Acar R; Sen E; Inal A; Turhal S; Kaya AO; Paydas S; Tastekin D; Hacibekiroglu I; Cincin I; Bilici A; Mandel NM; Dede DS; Akinci MB; Oksuzoglu B; Uncu D; Yalcin B; Artac M
    J Cancer Res Ther; 2022 Dec; 18(12 Suppl 2):S347-S353. PubMed ID: 36510987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.
    Delbaldo C; Ychou M; Zawadi A; Douillard JY; André T; Guerin-Meyer V; Rougier P; Dupuis O; Faroux R; Jouhaud A; Quinaux E; Buyse M; Piedbois P
    Ann Oncol; 2015 Jun; 26(6):1208-1215. PubMed ID: 25739671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
    Ginzac A; Thivat E; Petorin C; Richard D; Herviou P; Molnar I; Devaud H; Creveaux I; Ferrer F; Authier N; Jary M; Pezet D; Durando X
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):225-236. PubMed ID: 37932443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI.
    Catalano M; Lavacchi D; Giommoni E; Shabani S; Guidolin A; Brugia M; Petrioli R; Ramello M; Pillozzi S; Antonuzzo L; Roviello G
    Future Oncol; 2023 Dec; 19(38):2537-2546. PubMed ID: 38050741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Mukherjee S; Fountzilas C; Boland PM; Gosain R; Attwood K; Tan W; Khushalani N; Iyer R
    Target Oncol; 2020 Feb; 15(1):85-92. PubMed ID: 31802410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
    Shaojun C; Li H; Haixin H; Guisheng L
    Cancer Biol Ther; 2018 Mar; 19(3):153-159. PubMed ID: 29261002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
    Tabernero J; Hozak RR; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Prausová J; Muro K; Siegel RW; Konrad RJ; Ouyang H; Melemed SA; Ferry D; Nasroulah F; Van Cutsem E
    Ann Oncol; 2018 Mar; 29(3):602-609. PubMed ID: 29228087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of FOLFIRI-Based First-Line Regimens for Metastatic Colorectal Cancer Using Clinical Decision Analysis.
    Shida T; Ono Y; Kobayashi Y; Ogura J; Hatakeyama S; Arakawa I; Inoue T; Yamaguchi H
    Gan To Kagaku Ryoho; 2024 May; 51(5):541-547. PubMed ID: 38881065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
    Taniguchi SH; Komine K; Takenaga N; Yoshida Y; Sasaki K; Kawamura Y; Kasahara Y; Ouchi K; Imai H; Saijo K; Shirota H; Takahashi M; Ishioka C
    Anticancer Res; 2023 Dec; 43(12):5699-5704. PubMed ID: 38030182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.